the aid library

LIST OPTIONS

Filter

3470

Sort by:

Direction:

Download (32)

View PDF (33)

Management of diabetes A national clinical guideline

Helthcare Improvement Scotland (2017) CC2

Diabetes mellitus is a major cause of morbidity and mortality in Scotland and worldwide, with an increasing prevalence. In 2009 there were around 228,000 people registered as having diabetes in Scotland, an increase of 3.6% from the preceding year. This increase relates, in part, to the increasing a... more

Download (28)

View PDF (36)

Summary of WHO infection prevention and control guideline for Ebola and Marburg disease: a call for evidence based practice

World Health Organisation (WHO) (2024) C_WHO

This article summarises the process involved in developing the updated guideline and includes an infographic to highlight key IPC recommendations from the guideline, following the patient care pathway from the community to a healthcare facility to discharge.

Download (37)

View PDF (42)

South African cardiovascular risk stratification guideline for non-cardiac surgery

Alphonsus, C.; Naidoo, N.; Motshabi, P. et al. South African Medical Journal (2021) CC

The South African (SA) guidelines for cardiac patients for non-cardiac surgery were developed to address the need for cardiac risk assessment and risk stratification for elective non-cardiac surgical patients in SA, and more broadly in Africa. The guidelines were developed by updating the Canadian ...Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Non-cardiac Surgery, with a search of literature from African countries and recent publications. The updated proposed guidelines were then evaluated in a Delphi consensus process by SA anaesthesia and vascular surgical experts. The recommendations in these guidelines are: 1. We suggest that elective non-cardiac surgical patients who are 45 years and older with either a history of coronary artery disease, congestive cardiac failure, stroke or transient ischaemic attack, or vascular surgical patients 18 years or older with peripheral vascular disease require further preoperative risk stratification as their predicted 30-day major adverse cardiac event (MACE) risk exceeds 5% (conditional recommendation: moderate-quality evidence). 2. We do not recommend routine non-invasive testing for cardiovascular risk stratification prior to elective non-cardiac surgery in adults (strong recommendation: low-to-moderate-quality evidence). 3. We recommend that elective non-cardiac surgical patients who are 45 years and older with a history of coronary artery disease, or stroke or transient ischaemic attack, or congestive cardiac failure or vascular surgical patients 18 years or older with peripheral vascular disease should have preoperative natriuretic peptide (NP) screening (strong recommendation: high-quality evidence). 4. We recommend daily postoperative troponin measurements for 48 - 72 hours for non-cardiac surgical patients who are 45 years and older with a history of coronary artery disease, or stroke or transient ischaemic attack, or congestive cardiac failure or vascular surgical patients 18 years or older with peripheral vascular disease, i.e. (i) a baseline risk >5% for MACE 30 days after elective surgery (if no preoperative NP screening), or (ii) an elevated B-type natriuretic peptide (BNP)/N-terminal-prohormone B-type natriuretic peptide (NT-proBNP) measurement before elective surgery (defined as BNP >99 pg/mL or a NT-proBNP >300 pg/mL) (conditional recommendation: moderate-quality evidence). Additional recommendations are given for the management of myocardial injury after non-cardiac surgery (MINS) and medications for comorbidities. more

Download (261)

View PDF (356)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (153)

View PDF (170)

Clinical management of COVID-19: Living guideline, 18 August 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important.

Download (113)

View PDF (138)

Clinical management of COVID-19: living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

As of 12 December 2022, over 645 million people worldwide have been diagnosed with COVID-19, with over 6.6 million deaths (4). The Omicron variant, which emerged in late November 2021, and its subvariants, are now the dominant circulating viruses, contributing to the ongoing surge in several countr... more

Download (177)

View PDF (149)

Clinical management of COVID-19: living guideline, 23 June 2022 (Arabic)
recommended

World Health Organization WHO (2022) C_WHO

Update, 23 de junio de 2022

Download (148)

View PDF (224)

Therapeutics and COVID-19: living guideline (Arabic)
recommended

World Health Organization WHO (2022) C_WHO

3 March 2022 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ... more

Download (117)

View PDF (140)

COVID-19 infection prevention and control living guideline: mask use in community settings, 22 December 2021

World Health Organization WHO (2021) C_WHO

22 December 2021

Download (113)

View PDF (132)

Management of covid-19: a practical guideline formaternal and newborn health care providers inSub-Saharan Africa

B. N. Ezenwa, I. B. Fajolu, O. R. Akinajo, et al. The Journal of Maternal-Fetal & Neonatal Medicine (2020) CC

COVID-19 is a pandemic that is currently ravaging the world. Infection rate is steadily increasingin Sub-Saharan Africa. Pregnant women and their infants may suffer severe illnesses due to theirlower immunity. This guideline prepares and equips clinicians working in the maternal and new-born section... more

Download (676)

View PDF (593)

Menstrual Hygiene Management in Ethiopia. An Inter-sectoral issue: Policy and Implementation Guideline

Ministry of Health, Ethiopia (2018) C1

Download (384)

View PDF (556)

Namibia: HIV and AIDS Mainstreaming Guideline for Sector Responses

Ministry of Health and Social Services (MOHSS) (2017) C2

Accessed November 2, 2017

Download (835)

View PDF (867)

Regional and District Level Program Implementation Guideline 2073-2074 Nepal

Ministry of Health, Nepal (2017) C1

Download (874)

View PDF (378)

National Hygiene and Environmental Health Communication Guideline

Ministry of Health, Ethiopia (2016) C1

Advocacy ,Social Mobilization ,Behavior Change Communications

Download (275)

View PDF (418)

INDEX-TB GUIDELINES: Evidence Summaries and Guideline Panel Decision Tables Core Group Guideline Meeting

(2016) C1

This document contains: The systematic reviews and GRADE assessments used at the Index-TB Guideline Panel in July 2015; The Evidence to Decision tables that record the Panel’s assessment and recommendations from this meeting

Download (578)

View PDF (1142)

Engaging Private Security Providers - A Guideline for Non-Governmental Organisations - Update 2015

Max Glaser, European Interagency Security Forum (EISF) (2015) C2

Corrections and updates to EISF Briefing Paper Engaging Private Security Providers. Engaging Private Security Providers: A Guideline for Non-Governmental Organisations was first published in December 2011. While this is not an exhaustive update, this document intends to reflect the most important de... more

Download (503)

View PDF (618)

Arrangement of disabled peoples rights. Explanation guideline. (Nepali Version)

NFD-N (National federation of the disabled- Nepal), My Right. Government of Nepal (2015) C1

Download (405)

View PDF (678)

Female community health volunteer fund operational guideline

Ministry of Health and Population, Family Health Division (2008) C1

Download (378)

View PDF (704)

India: Voluntary Blood Donation Programme - An Operational Guideline

National AIDS Control Organisation (NACO), Ministry of Health and Family Welfare (MOHFW), Government of India (2007) C1

Download (116)

View PDF (106)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Clinical management of COVID-19: living guideline, 23 June 2022 (Arabic) recommended

Therapeutics and COVID-19: living guideline (Arabic) recommended

Clinical management of COVID-19: living guideline, 23 June 2022 (Arabic)
recommended

Therapeutics and COVID-19: living guideline (Arabic)
recommended